[HTML][HTML] Cost-effectiveness analysis alongside clinical trials II—an ISPOR Good Research Practices Task Force report

SD Ramsey, RJ Willke, H Glick, SD Reed… - Value in health, 2015 - Elsevier
Clinical trials evaluating medicines, medical devices, and procedures now commonly
assess the economic value of these interventions. The growing number of prospective …

Good research practices for cost‐effectiveness analysis alongside clinical trials: the ISPOR RCT‐CEA Task Force report

S Ramsey, R Willke, A Briggs, R Brown… - Value in …, 2005 - Wiley Online Library
Objectives: A growing number of prospective clinical trials include economic end points.
Recognizing the variation in methodology and reporting of these studies, the International …

Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation

S Odes, H Vardi, M Friger, F Wolters, MG Russel, L Riis… - Gastroenterology, 2006 - Elsevier
Background & Aims: Economic analysis in chronic diseases is a prerequisite for planning a
proper distribution of health care resources. We aimed to determine the cost of inflammatory …

[HTML][HTML] VenUS IV (Venous leg Ulcer Study IV)-compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised …

RL Ashby, R Gabe, S Ali, P Saramago… - Health technology …, 2014 - ncbi.nlm.nih.gov
BACKGROUND Compression is an effective and recommended treatment for venous leg
ulcers. Although the four-layer bandage (4LB) is regarded as the gold standard compression …

Costs associated with resource utilization during the palliative phase of care: a Canadian perspective

S Dumont, P Jacobs, K Fassbender… - Palliative …, 2009 - journals.sagepub.com
Objective: This study aimed to evaluate prospectively the resource utilization and related
costs during the palliative phase of care in five regions across Canada. Subjects: A cohort of …

[图书][B] Estimating costs and valuations of non-health benefits in cost-effectiveness analysis

A Basu - 2017 - books.google.com
This chapter examines the process of identifying, quantifying, and valuing the resource costs
associated with healthcare interventions that arise due to the use and consequences of …

The ISPOR good practices for quality improvement of cost‐effectiveness research task force report

WF McGhan, M Al, JA Doshi, I Kamae, SE Marx… - Value in …, 2009 - Wiley Online Library
ABSTRACT Objectives: The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Health Science Policy Council recommended and the ISPOR Board of …

Techniques for estimating health care costs with censored data: an overview for the health services researcher

HC Wijeysundera, X Wang, G Tomlinson… - ClinicoEconomics …, 2012 - Taylor & Francis
Objective The aim of this study was to review statistical techniques for estimating the mean
population cost using health care cost data that, because of the inability to achieve complete …

Estimating lifetime or episode‐of‐illness costs under censoring

A Basu, WG Manning - Health economics, 2010 - Wiley Online Library
Many analyses of healthcare costs involve use of data with varying periods of observation
and right censoring of cases before death or at the end of the episode of illness. The …

Analyses of cost data in economic evaluations conducted alongside randomized controlled trials

JA Doshi, HA Glick, D Polsky - Value in Health, 2006 - Wiley Online Library
Objective: The adoption and diffusion of new medical treatments depend increasingly on
evidence of costs and cost‐effectiveness. This evidence is increasingly being generated …